CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled / 53 target
Drug / intervention
500 mg NDS-446drug
Likely dose
500 mg NDS-446from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05557279
NCT05557279Phase 2CompletedOn Track (1.3/mo)Completion was 10mo ago
CompareCT.gov

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks - a Single-center Study

Loyola University·interventional·Posted Sep 28, 2022·Updated Jun 17, 2026

In Brief

A Phase 2 clinical trial evaluating 500 mg NDS-446 for Overactive Bladder. Completed, enrolled 53 participants across 1 site.

Detailed Summary

The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedSep 28, 2022
Enrollment StartJan 1, 2023
Primary CompletionAug 11, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 3.8 years ago

Arms & Interventions

Intervention Groupother

All participants will receive 500 mg NDS-446 daily for 12 weeks

Drug: 500 mg NDS-446

Interventions

500 mg NDS-446drug

All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment